Interaction Checker

Interações de Octreotida

Octreotida (Sandostatin, Bynfezia, Mycapssa) tem 125 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 0; moderadas: 125; leves: 0; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações moderadas (125)

  • AcarboseantidiabéticoModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • AcebutololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Alogliptinainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Alogliptina + metforminainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Anlodipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Anlodipino + atorvastatinabloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Anlodipino + benazeprilbloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Anlodipino + olmesartanabloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Anlodipino + valsartanabloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Produtos de venda livreModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • AtenololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Atenolol + clortalidonabetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • BetaxololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Bexagliflozinainibidor do SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Bicarbonato de sódioantiácidoModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • BisoprololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Bisoprolol + hidroclorotiazidabetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Brimonidina + timololagonista alfa-adrenérgicoModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Bromocriptinaagonista da dopaminaModerada

    Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Canagliflozinainibidor do SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • CarvedilolbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • CiclosporinaimunossupressorModerada

    Cyclosporine : may have decreased bioavailability and require dose adjustment ( 7 ). (bula de Octreotida, Interações medicamentosas)

  • Cimetidinabloqueador H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Dapagliflozinainibidor do SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Dapagliflozina + metforminainibidor do SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Desogestrel + etinilestradiolanticoncepcional oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Dexlansoprazolinibidor da bomba de prótonsModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Dextrometorfano + quinidinamedicamento serotoninérgicoModerada

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Diacetato de etinodiol + etinilestradiolanticoncepcional oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Digoxinaglicosídeo digitálicoModerada

    Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Diltiazembloqueador dos canais de cálcioModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Dorzolamida + timololinibidor da anidrase carbônicaModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Drospirenona + etinilestradiolanticoncepcional oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Dulaglutidaagonista do receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Empagliflozinainibidor do SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Empagliflozina + metforminainibidor do SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • EsmololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Esomeprazolinibidor da bomba de prótonsModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • EstradiolestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Estradiol + dienogesteanticoncepcional oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Estradiol + noretisteronaestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Estrogênios conjugadosestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Estrogênios conjugados + bazedoxifenoestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Estrogênios esterificados + metiltestosteronaestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Etonogestrel + etinilestradiolestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Exenatidaagonista do receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Famotidinabloqueador H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Felodipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • FulvestrantoestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • GlibenclamidasulfonilureiaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Glibenclamida + metforminasulfonilureiaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • GlimepiridasulfonilureiaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • GlipizidasulfonilureiaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Glipizida + metforminasulfonilureiaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • GlucagonModerada

    Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (bula de Octreotida, Advertências e precauções)

  • Ibuprofeno + famotidinaAINEModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Insulina asparteinsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Insulina degludecainsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Insulina detemirinsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Insulina glarginainsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Insulina lisproinsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Insulina regular (humana)insulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Isradipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • LabetalolbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Lansoprazolinibidor da bomba de prótonsModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • LevonorgestrelprogestinaModerada

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (bula de Octreotida, Interações medicamentosas)

  • Levonorgestrel + etinilestradiolanticoncepcional oralModerada

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (bula de Octreotida, Interações medicamentosas)

  • Levotiroxinahormônio tireoidianoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (bula de Octreotida, Advertências e precauções)

  • Levotiroxina + liotironinahormônio tireoidianoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (bula de Octreotida, Advertências e precauções)

  • Linagliptinainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Linagliptina + metforminainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Liotironinahormônio tireoidianoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (bula de Octreotida, Advertências e precauções)

  • Liraglutidaagonista do receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Lisinoprilinibidor da ECAModerada

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Lisinopril + hidroclorotiazidainibidor da ECAModerada

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • MedroxiprogesteronaprogestinaModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • MegestrolprogestinaModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • MetforminabiguanidaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • MetoprololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Metoprolol + hidroclorotiazidabetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Mifepristonainibidor da CYP3A4Moderada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • MiglitolantidiabéticoModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • NadololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Naproxeno + esomeprazolAINEModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • NateglinidameglitinidaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • NebivololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Nicardipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Nifedipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Nimodipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Nisoldipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Nizatidinabloqueador H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Norelgestromina + etinilestradiolestrogênioModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • NoretisteronaprogestinaModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Noretisterona + etinilestradiolanticoncepcional oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Norgestimato + etinilestradiolanticoncepcional oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Norgestrel + etinilestradiolanticoncepcional oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Olmesartana + anlodipino + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Moderada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Omeprazolinibidor da bomba de prótonsModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Omeprazol + bicarbonato de sódioinibidor da bomba de prótonsModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Pantoprazolinibidor da bomba de prótonsModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • PindololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • PioglitazonatiazolidinedionaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Pioglitazona + glimepiridatiazolidinedionaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Pioglitazona + metforminatiazolidinedionaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • ProgesteronaprogestinaModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (bula de Octreotida, Interações medicamentosas)

  • Propiltiouracilamedicamento antitireoidianoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (bula de Octreotida, Advertências e precauções)

  • PropranololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • QuinidinaantiarrítmicoModerada

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Rabeprazolinibidor da bomba de prótonsModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Ranitidinabloqueador H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • RepaglinidameglitinidaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Saxagliptinainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Saxagliptina + metforminainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Semaglutidaagonista do receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Sitagliptinainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Sitagliptina + metforminainibidor da DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • SotalolbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Telmisartana + anlodipinobloqueador do receptor da angiotensina II (BRA)Moderada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • TelotristateModerada

    Short-Acting Octreotide Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite. (bula de Telotristate, Interações medicamentosas)

  • Teriparatidahormônio tireoidianoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (bula de Octreotida, Advertências e precauções)

  • Tiamazol (metimazol)medicamento antitireoidianoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (bula de Octreotida, Advertências e precauções)

  • TimololbetabloqueadorModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (bula de Octreotida, Advertências e precauções)

  • Tirzepatidaagonista do receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

  • Verapamilbloqueador dos canais de cálcioModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

  • Vitamina B12Vitaminas e mineraisModerada

    Change in vitamin B12 levels: Monitor vitamin B 12 levels during treatment ( 5.6 ). (bula de Octreotida, Advertências e precauções)

Verifique Octreotida com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.